Arabinofuranosyl residue (Araf)

Arabinofuranosyl residues are five-carbon sugar moieties in a furanose ring form that serve as essential structural building blocks in the cell walls of Mycobacteria, including Mycobacterium tuberculosis. These residues are primarily organized into complex polysaccharides such as arabinogalactan and lipoarabinomannan, which are critical for maintaining the bacterial cell wall's integrity and protecting the organism from environmental stress and host immune responses. Because the biosynthetic pathways for D-arabinofuranose are unique to bacteria and absent in humans, they represent highly selective and validated therapeutic targets for antimicrobial development. The frontline antitubercular drug Ethambutol specifically targets the incorporation of these residues by inhibiting arabinosyltransferases, leading to a compromised cell wall and bacterial cell death. Beyond their role as a structural scaffold, arabinofuranosyl-containing glycans are significant for their immunomodulatory properties and serve as clinical biomarkers; for instance, the detection of lipoarabinomannan in urine is a WHO-recommended diagnostic tool for tuberculosis in immunocompromised patients. Ongoing research continues to explore these residues as epitopes for carbohydrate-based vaccines and novel small-molecule inhibitors to combat multi-drug-resistant mycobacterial strains.

Other names

D-ArabinofuranoseArabinofuranosyl groupArabinofuranosyl moietyalpha-D-Arabinofuranosebeta-D-Arabinofuranose

Inhibition of arabinosyltransferase enzymes (EmbA, EmbB, and EmbC) which prevents the polymerization of arabinofuranosyl residues into the arabinogalactan and lipoarabinomannan layers of the mycobacterial cell wall.